Monday, 12 July 2010

Proprietary skincare technology platform reaches market , July 12 /PRNewswire/ -- Signum Biosciences announced that its partner, Rohto Pharmaceutical Co., Ltd., has launched AFC Medirepair® with Signum's compound Arazine™ (n-acetyl-s-farnsylcysteine or AFC) in . Arazine™ is the first compound from Signum's novel anti-inflammatory platform to be commercialized from Signum's pipeline of Signal Transduction Modulators (STMs). The DRx AFC Medirepair® website can be found at: http://www.drx-web.com/aa/prod_afc.htm ....
http://www.k2pedia.com/asia/55756-signum-biosciences-inc-announces-commercial-launch-of-arazine%E2%84%A2
Posted by at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)